Wave Life Sciences Ltd. (NASDAQ: WVE) reported interim data from its Phase 1 INLIGHT trial showing that a single 240 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA

RBC on WAVE Life Sciences (WVE): 't we continue to see a molecule that is pharmacologically active and remain optimistic'March 27, 2026 5:04 AM B.Riley on WAVE Life Sciences (WVE): 'a ~60% intraday selloff that, in our view, is significantly overdone'March 26, 2026 12:23 PM Jefferies on WAVE Life Sciences (WVE): 'near-term pressure on stock'March 26, 2026 9:37 AM